Diindolilmethane (DIM) selectively inhibits cancer stem cells

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Epidemiologic studies link cruciferous vegetables to cancer chemoprevention.
• Indole-3-carbinol (I3C) and its metabolite diindolylmethane (DIM) are key active compounds.
• Previous research confirmed the anti-tumor activities of I3C and DIM in vitro and in vivo.

Purpose of the Study:

• To investigate diindolylmethane (DIM) as a selective inhibitor of cancer stem cells (CSCs).
• To evaluate DIM's efficacy in overcoming CSC chemoresistance.
• To assess the therapeutic potential of DIM in preclinical cancer models.

Main Methods:

• Assessing DIM's effect on tumor sphere formation in various cancer cell lines.
• Evaluating DIM's ability to overcome chemoresistance to paclitaxel, doxorubicin, and SN-38 in CSCs.
• Testing DIM's efficacy in a mouse model by pre-treating tumor spheres before implantation.

Main Results:

• DIM potently inhibited CSC tumor sphere formation at significantly lower concentrations than those affecting parental cells.
• DIM treatment reversed chemoresistance in CSCs against common cytotoxic drugs.
• Pre-treatment with DIM significantly retarded primary tumor growth in vivo.
• Achievable plasma concentrations of DIM align with those effective against CSCs.

Conclusions:

• Diindolylmethane (DIM) is a potent and selective inhibitor of cancer stem cells (CSCs).
• DIM demonstrates potential in overcoming CSC chemoresistance and reducing tumor growth.
• DIM shows promise as a therapeutic agent for cancer patients, potentially in combination therapies.